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Spatial and temporal homogeneity of driver
mutations in diffuse intrinsic pontine glioma
Hamid Nikbakht1,2,*, Eshini Panditharatna3,4,*, Leonie G. Mikael5,*, Rui Li1,2, Tenzin Gayden1,
Matthew Osmond1,2, Cheng-Ying Ho6, Madhuri Kambhampati3, Eugene I. Hwang7, Damien Faury5,
Alan Siu8, Simon Papillon-Cavanagh1,2, Denise Bechet1, Keith L. Ligon9, Benjamin Ellezam10,
Wendy J. Ingram11, Caedyn Stinson12, Andrew S. Moore11,12,13, Katherine E. Warren14,
Jason Karamchandani15, Roger J. Packer16, Nada Jabado1,5,**, Jacek Majewski1,2,** & Javad Nazarian3,17,**

Diffuse Intrinsic Pontine Gliomas (DIPGs) are deadly paediatric brain tumours where needle
biopsies help guide diagnosis and targeted therapies. To address spatial heterogeneity,
here we analyse 134 specimens from various neuroanatomical structures of whole autopsy
brains from nine DIPG patients. Evolutionary reconstruction indicates histone 3 (H3)
K27M—including H3.2K27M—mutations potentially arise ﬁrst and are invariably associated
with speciﬁc, high-ﬁdelity obligate partners throughout the tumour and its spread, from
diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M
ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D)
or speciﬁc growth factor pathways (ACVR1/PIK3R1). Later oncogenic alterations arise in
sub-clones and often affect the PI3K pathway. Our ﬁndings are consistent with early tumour
spread outside the brainstem including the cerebrum. The spatial and temporal homogeneity
of main driver mutations in DIPG implies they will be captured by limited biopsies and
emphasizes the need to develop therapies speciﬁcally targeting obligate oncohistone
partnerships.
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Pathology, Montreal Neurological Hospital, McGill University, Montreal, Québec, Canada H3A 2B4. 16 Brain Tumour Institute, Center for Neuroscience and
Behavioral Medicine, Children’s National Health System, Washington, District Of Columbia, 20010, USA. 17 Department of Integrative Systems Biology,
George Washington University School of Medicine and Health Sciences, Washington, District Of Columbia 20052, USA. * These authors contributed equally
to this work. ** These authors jointly supervised this work. Correspondence and requests for materials should be addressed to N.J.
(email: nada.jabado@mcgill.ca) or to J.M. (email: Jacek.majewski@mcgill.ca) or to J.N. (email: JNazarian@childrensnational.org).

NATURE COMMUNICATIONS | 7:11185 | DOI: 10.1038/ncomms11185 | www.nature.com/naturecommunications

1

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11185

D

iffuse Intrinsic Pontine Gliomas (DIPGs) represent
10–15% of all paediatric brain tumours and have a
dismal median survival of 9–12 months. They seemingly
arise as de novo tumours in the pons where surgical options are
limited1,2. Recently, we and others have identiﬁed recurrent
somatic gain-of-function mutations leading to lysine 27 to
methionine (p.Lys27Met, K27M) substitution in histone H3 in
B80% of DIPGs2–4. Despite a low mutational rate relative to
other cancers, these H3K27M mutants appear to be often
associated with other mutations in cell cycle regulatory genes
(TP53, PPM1D), chromatin remodeler (ATRX) or growth factors
(ACVR1) (refs 3–8).
Spatial and temporal tumour heterogeneity is viewed as a major
obstacle to accurate diagnosis and successful targeted therapy in
cancer. Many adult cancers including high-grade gliomas (HGG)
show intra-tumour heterogeneity9–11, which confounds
determining the complete genetic landscape when only a fraction
of a tumour is sampled. In DIPG, published studies have solely
used biopsied or limited autopsied specimens without assessing the
full spatial and temporal tumour heterogeneity. Despite the fact
that H3K27M mutations are identiﬁed in most DIPG tumour
samples2–8,12, the homogeneity of histone and its partner
mutation(s) across tumour mass is yet to be determined. It is
not currently clear to what extent the tumour may be composed of
a mixture of clonal populations carrying distinct mutations. In
addition, while DIPGs invariably exhibit tumour spread outside of
the pons and brainstem13, there are to date no comprehensive
molecular studies of these invading cells. Such inﬁltrating tumour
cells may originate from speciﬁc clones present in the primary site,
as described for other cancers14 including other paediatric
tumours15,16. Alternately, malignant cells may seed early during
tumour evolution, as recently shown for low-grade gliomas in
adults17 and/or may genetically diverge from the primary tumour
as seen in metastatic cancer including medulloblastoma16.
Therefore, in order to deﬁne DIPG heterogeneity, we sought to:
(i) determine whether the currently recommended needle
biopsies18 robustly deﬁne DIPG tumour biology; (ii) infer the
temporal order of speciﬁc driver mutations in DIPG; and
(iii) fully characterize the molecular signature of the primary,
regional and distant subclones, and deﬁne their evolutionary
relationships. Our results suggest that histone H3K27M mutations
arise ﬁrst and are associated with speciﬁc, obligate partners
involving alterations in TP53 cell-cycle (TP53/PPM1D) or speciﬁc
growth factor pathways (ACVR1/PIK3R1), which are present
throughout the tumour as well as its spread outside the brainstem.
Results
Genomic landscape of primary and extended tumours.
We analysed 134 punch cores from nine DIPG whole brain
specimens obtained at autopsy as previously described19. Selected
punch cores represented multiple spatial regions of the primary
tumour and adjacent areas within the brainstem (average of
six per autopsy encompassing the pons, midbrain and medulla),
cerebellum and various cerebral neuroanatomical regions
(average of 10 per autopsy) (Supplementary Tables 1–3;
Supplementary Fig. 1). Sixty-seven samples representative of
tumour and normal brain areas based on histological assessment
were subjected to whole exome sequencing (WES) (Fig. 1;
Supplementary Tables 1–4 and Supplementary Data 1–9,
Supplementary Fig. 2). Oncogenic mutations associated with
HGG3,5–8 were identiﬁed in 41/67 (61%) of punch cores and a
vast majority (35/37; 95%) of punch cores taken from the
brainstem (Supplementary Tables 1 and 2). Surprisingly, samples
with oncogenic mutations also included distal supratentorial
areas (3/20), a few of which were deemed radiologically and
2

histologically normal (Fig. 1, Supplementary Tables 1–3,
Supplementary Figs 2A–E and 4). In eight DIPGs, we observed
K27M mutations in canonical H3.1 (2/8) or non-canonical H3.3
(6/8). In one patient, we identiﬁed K27M in HIST2H3C, which
encodes the canonical histone 3.2 (H3.2K27M) (Fig. 1) a novel
mutation recently described in one paediatric DIPG sample20.
H3K27M mutations were ubiquitous in all 41 samples with
oncogenic content, and were always associated with at least one
additional partner driver mutation: TP53, PPM1D, ACVR1 or
PIK3R1 (Fig. 1).
Clonal evolution of diffuse intrinsic pontine glioma. To
decipher clonal evolution of DIPG, we employed a strategy
resembling previously successful multi-region tumour sequencing
studies14. Such approaches aim to reconstruct evolutionary
relationship among multiple samples from the same patient based
on the presence or absence of newly emerging somatic
mutations14,17, and the relative mutation allele frequencies21,22.
We used our WES data (70  mean coverage) to select mutations—
based on their presence in our and other available DIPG
datasets3,5–8—for further screening using deep amplicon
sequencing (B4,000  mean coverage) in the initial sample set
and in other geographically proximal and distal samples (N ¼ 134).
Mutation allele frequencies were corrected for aneuploidy and
presence within copy number variant (CNV) regions whenever
possible, and subsequently used to reconstruct evolutionary
trajectories (Fig. 2; Supplementary Figs 5, 6 and 7; Supplementary
Table 5). Remarkably, evolutionary analysis showed obligate
association of speciﬁc combinations of at least four primary
partner driver genes in our sample set: H3K27M/TP53 and/or
PPM1D, H3K27M/ACVR1 and H3K27M/PIK3R1 (Fig. 2;
Supplementary Fig. 7). The association between the histone
mutation and obligate partner(s) was invariably maintained
throughout all samples from an autopsy brain. This is in striking
contrast to adult cancers, including HGG, which have large
numbers of mutations and potentially long evolutionary histories
resulting in complex clonal structures9,10,17. This also contrasts
isocitrate dehydrogenase (IDH)-mediated tumorigenesis, where
IDH mutations are associated with genetic alterations that change
over the course of the disease either through partnership with a
different mutated gene or through acquisition of additional/
different mutations in the same gene during tumour evolution17.
Temporal tumour homogeneity of main driver mutations. The
tight association of principal driver mutation pairs implies early
and nearly concurrent appearance during tumour evolution.
Accordingly, in several cases the order of the partner mutations
could not be resolved (Fig. 2; Supplementary Fig. 7). However,
variations in the relative allele frequencies across spatial samples
in DIPG1, DIPG5, DIPG7 and DIPG9 enabled estimation of the
most likely mutation order, suggesting H3K27M as the earliest
tumorigenic event in DIPG (Fig. 2, Supplementary Fig. 7). A clear
example of such clonal evolution is illustrated by DIPG5 (Fig. 2a)
harboring three principal driver mutations (H3.3K27M/TP53/
PPM1D). PPM1D regulates TP53 cell-cycle checkpoint and
mutations in both genes have been described as mutually exclusive in gliomas8,23. DIPG5 is the sole reported exception to this
rule, providing valuable evolutionary insights. We identiﬁed two
major clones carrying distinct combinations of driver mutations,
H3.3K27M-TP53 and H3.3K27M-PPM1D, indicating the
H3.3K27M mutation as the initial event, followed by TP53
mutation in one subclone, and PPM1D mutation in another. This
suggests that the early presence of oncohistone mutations
promotes subsequent alterations of the TP53 pathway, and that
this partner association—which is required for full transforming
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Figure 1 | Oncogenic alterations in 41 sub-regions from nine DIPG patients from whole exome sequencing data. Samples representing different
anatomical locations within each patient are represented in columns. The mutations (in rows) were selected based on published datasets in paediatric
glioblastoma and speciﬁcally DIPG. Mutations were divided into two subgroups; driver mutations which are essential for tumour initiation/maintenance and
accessory driver mutations, which can further promote and accelerate tumour growth, but are not absolutely essential for tumour initiation or maintenance.

potential in DIPG—is subsequently maintained throughout the
tumour.
Further analysis of combined data from our cohort and
published genomic DIPG datasets (N ¼ 130) showed the presence
of H3K27M in 116/130 (89%) of patients (29 H3.1K27M,
1 H3.2K27M, 86 H3.3K27M, Supplementary Table 6 and
Supplementary Fig. 10). H3K27M mutants were in vast majority
of cases (111/116) associated with partner mutations, which
included the TP53 pathway exclusively (71), growth factor
pathways exclusively (28), or a combination of both (11).
Mutations in TP53 (64), PPM1D (9), TP53 and PPM1D
(1, DIPG5), or other genes controlling this cell-cycle checkpoint
(1) were preferentially associated with H3.3K27M. Recurrent
activating ACVR1 somatic mutations were identiﬁed in 32
H3K27M samples, including eight with TP53 pathway mutations.
These mutations, as previously shown, tend to favor association
with the canonical H3K27M (25/32). In rare cases including one
from our dataset (DIPG1), we identiﬁed H3K27M/PIK3R1
association as the main combination of driver mutations
(3/111) (Supplementary Table 6 and Supplementary Fig. 10).
A novel CTNNA2 alteration was also identiﬁed as clonal in
DIPG1 similar to PIK3R1. Even if we cannot fully rule out its
contribution to tumorigenesis, it was not viewed as main driver as
no clear phenotypic advantage could be inferred. Furthermore,
this mutation has not been previously reported in COSMIC and
was absent in other DIPG samples including other datasets
analysed in this study (Fig. 1, Supplementary Table 7).
In order to assess the ﬁdelity of postmortem specimen as
representative of newly diagnosed tumours, we analysed three
available paired biopsy/autopsy samples (Supplementary Table 7).
In all cases, H3K27M mutants and their obligate partners were
present both at diagnosis and at the end-stage of the disease.

This ﬁnding, along with the analysis of published diagnosis
biopsy datasets3,5–8, indicates that the H3K27M obligate
partnership is maintained throughout the disease course.
Molecular characterization of tumour spread. Molecular studies
of punch cores representing various neuroanatomical locations
showed tumour extension outside the brainstem (Supplementary
Tables 1–3; Supplementary Fig. 3). Remarkably, tumour spread
was detected in proximal (for example, the cerebellum, 4/8
patients with sampled material) and distal (thalamus 4/4,
hippocampus/ventricle/frontal or occipital lobes 3/7) brain
locations, and in rare cases in areas with no clinical, radiological
or histopathological evidence of tumour (Supplementary Figs 2,
3, 4). Interestingly, re-analysis of the published datasets showed
two cases where the matched ‘normal’ frontal lobe samples had
H3K27M/partner mutation frequencies similar to the primary
tumour5. Furthermore, clustering analysis of our DNA
methylation data showed distant tumour spread to be more
similar to H3K27M mutant tumours than to normal brain
(Supplementary Fig. 8). Thus, molecular designation of
histologically ‘normal’ brain DIPG specimen warrants more
in-depth molecular scrutiny. Evolutionary studies of tumour
dissemination were consistent with a mixture of early and late
tumour spread. Some sites harbored most of the secondary
mutations observed in the primary tumours suggestive of late
spread, while others lacked the secondary mutations found in
the primary tumour site suggestive of early spread (Fig. 3a,
Supplementary Fig. 9).
In addition to the main driver mutations discussed above,
several patients carry recurrent mutations that are clearly
subclonal (present in some but not all tumour areas in a patient)
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Figure 2 | Selected examples of clonal evolution within DIPG tumours. Left: histograms show the raw allele frequencies (whole exome sequencing data)
for each somatic mutation in different autopsy regions within each tumour. Red: ubiquitous mutations across regions; yellow: mutations shared in at least
two regions; blue: mutations seen in only one region. Right: phylogenetic trees constructed from the mutation allele frequencies of deep amplicon
sequencing data showing the order of evolution along with support probabilities (upper portions of graphs) and clonal mixing proportions within samples
(lower portions). For clarity, only mutations selected to be likely oncogenic are shown. (a) DIPG5: a rare case harboring both TP53 and PPM1D mutations,
which are generally found to be mutually exclusive. PPM1D and TP53 mutations occur in distinct clones and are both secondary to H3K27M. ATRX is also
secondary and subclonal. (b) DIPG6: while it is impossible to resolve the order of H3/TP53/ATRX mutations’ appearance, PIK3CA is clearly sub-clonal and
appears in the later stages of evolution within this tumour. (c) DIPG2: the H3.1 K27M and ACVR1 main driver mutations are ubiquitous, occur at similar
frequencies across all samples, and their mutation order cannot be resolved. Conversely, other accessory driver mutations are clearly secondary in order of
appearance, and are present only in distinct subclones.

and occur at later stages of tumour evolution (Fig. 1). These
include mutations in the chromatin remodeler ATRX (DIPG5
and DIPG9), as well as the activating PIK3CA H1047R
mutation24, which affects the catalytic domain of PIK3CA
(DIPG2, DIPG3 and DIPG6) (Fig. 1). In DIPG3 gross visual
inspection of the pons indicated two morphologically distinct
areas (Pons 1 and 2, Fig. 3b). Histological examination identiﬁed
area Pons 1 as low-grade inﬁltrative astrocytoma (WHO II) and
Pons 2 as high-grade astrocytoma (WHO IV, glioblastoma,
Fig. 3b). Both areas carried HIST2H3C/ACVR1 mutations
inferred to occur early in tumour evolution (Fig. 3b). However,
only Pons 2 (WHO IV) carried PIK3CA H1047R. RNAseq
analyses showed enrichment of overexpressed genes involved in
vasculature development and angiogenesis pathways in Pons 2,
in keeping with prior studies linking PI3K activation to
4

angiogenesis25 (Supplementary Data 10). Alterations affecting
the PI3K pathway are prevalent both in our sample set (4/9) and
in published DIPG datasets (31/116, 26%). Our data suggests
that PIK3CA mutations are not essential to tumour initiation in
DIPG but may confer localized survival, growth and angiogenic
advantage in the areas they are subsequently acquired.
Discussion
Genomic analysis of autopsy DIPG brains provides a fascinating
opportunity to reconstruct the evolution of this deadly tumour,
and has important implications on potential therapeutic interventions. Despite the sample number limitation based on disease
incidence, this study provides insight into the spatial and
temporal evolution of the tumour genome in DIPG helping
derive a general model for this disease.
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Figure 3 | Tumour spread in DIPG. (a) Tumour spread in DIPG2 in the thalamus, cerebellum and brainstem. Tumour extension in the thalamus harbors
secondary mutation PIK3CA, MAX and PTEN, which indicates late spread from both Pons 1 and Pons 2. Extension towards the cerebellum is relatively early
in the tumour evolution as it lacks secondary mutations found in the primary tumour and other brainstem spread. (b) Evolution of tumour in patient DIPG3.
Autopsy revealed two morphologically and histologically distinct regions of the tumour, indicated as DIPG3 Pons 1 (low-grade) and DIPG3 Pons 2
(high-grade). Exome sequencing identiﬁed 11 SNVs and several large scale CNAs common to both regions. Shared alterations included H3.2 K27M and
ACVR1 G328V mutations that are likely the main driver mutations in this patient. The analysis also indicated a clear clonal substructure of the two regions,
with 18 SNVs and 1 CNA found only in DIPG3 Pons 1, and 11 SNVs and 3 CNAs unique to DIPG3 Pons 2. Intriguingly, DIPG3 Pons 2 carries the activating
PIK3CA H1047R mutation, which occurs early in the evolution of this sub-clone judging by its high allelic frequency. PIK3CA H1047R is associated with
multi-potency24 and PI3K activation with angiogenesis and growth and this mutation likely contributes to tumour aggressiveness and high-grade features
of Pons 2 compared with Pons 1 in DIPG3. Scale bar ¼ 500 mm.

Our analysis suggests that H3K27M mutations are the initial
oncogenic event in DIPGs. However, these mutations are not
solely sufﬁcient for tumour formation, as they require, nearly
universally, obligate partners for effective tumorigenesis. There is
some disagreement in the cancer ﬁeld as to the deﬁnition of
‘driver’ versus ‘passenger’ mutations. The designation passenger
has been used for any variant that is not absolutely essential to the
tumorigenesis. However, for the purpose of this study—and
more generally—we postulate three categories of mutations:
(1) main driver mutations are essential to initiate and continue
tumorigenesis; (2) accessory driver mutations can further
promote and accelerate tumour growth but are not absolutely
essential; (3) passenger mutations are neutral and do not affect
the tumour. H3K27M and their obligate partners appear thus to
be the main driver mutations, since they always co-occur together
throughout each tumour.
These K27MH3.3 partner mutations are mostly genetic
alterations affecting the TP53 pathway, mainly TP53 and
less frequently PPM1D genes. H3K27M mutants also favor
association with ACVR1 gain of function mutations and in rare
cases (1 in our dataset and 2 in other reported cases) PIK3R1
mutations. Interestingly, even if more frequent, PIK3CA

mutations, including PIK3CA H1047R, clearly fall into the
accessory driver category, since they were invariably sub-clonal in
our dataset and in some other reported cases. Similarly, a PTEN
mutation was also found in some but not all tumour areas in
DIPG2 (Fig. 3). We can only speculate at this time as to why
mutations that ultimately activate the PI3K/AKT pathway appear
clonal for some of the component genes and subclonal for others.
This may be related to the dosage effect of pathway activation, as
the loss of the regulatory unit (PIK3R1) leads to increased
baseline activity of the wild-type kinase whereas the PIK3CA
H1047R mutation has been associated with higher kinase activity
and oncogenic potential through cellular reprograming and
induction of stemness properties24. Further studies are needed
to help ascertain the speciﬁc role of these accessory driver
mutations in oncohistone tumorigenesis.
Once acquired, the main driver partnership is maintained
throughout the course of the disease (diagnosis to autopsy), in all
cells across the primary tumour site, and in tumour spread
throughout the brain. The obligate partner is not chosen
randomly. One speculation about the phenotypic advantage of
the gain of additional mutations may be that the partners are
selected as those best suited to increase levels of mutant H3 in
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cells. Indeed, H3K27M mutants show a dose-dependent effect in
inducing cellular proliferation26,27. Canonical H3 variants are the
most abundant histones in cells and need cell-cycle division
(S-phase) for synthesis, whereas non-canonical H3.3 variants
represent B5% of all H3 in cells and are present throughout the
cell cycle. Accordingly, H3K27M mutations in cell cycledependent canonical histones may co-occur with alterations
affecting ACVR1, a growth factor that induces cell division,
resulting in the synthesis of wildtype and mutant H3.1 proteins.
H3K27M mutations in the non-canonical H3.3 histone are
mainly associated with mutations affecting the TP53 pathway, as
these possibly offer evasion from cell death and senescence and
provide the needed opportunity for the mutant H3.3K27M to
exert its effect over a longer period, effectively reshaping the
epigenome and drive tumour formation.
The previously unsuspected homogeneity for main driver
mutations across the course of the disease uncovered in this study
indicate that efforts to cure DIPG should be directed at the
oncohistone partnership, as other genetic alterations are generally
sub-clonal. Our ﬁndings further indicate that needle biopsies
recommended to orient care are representative of the main
drivers in DIPG even if the regional heterogeneity of other
secondary targetable alterations, such as PIK3CA mutations, may
not be fully captured. Based on early tumour spread, efforts to
cure DIPG should aim for early systemic tumour control as
opposed to regimens focused on the pons.
Methods
Patient samples. All patient samples were collected with informed consent in
accordance with the respective Ethics Review Boards of the Children’s National Health
System, Washington, DC, USA and the University of Queensland Child Health
Research Center, Brisbane, Australia. DIPG post-mortem specimen procurement was
performed as previously described19. Brieﬂy, the brainstem and cerebellum were
removed en bloc from the whole brain, and dissected into B9 transverse sections. The
cerebral cortex was dissected into B11 coronal sections. The brainstem, cerebellum
and cerebral cortex sections were alternatively frozen or ﬁxed in formalin. A total of
158 samples were studied by immunohistochemistry and molecular analyses,
representing various neuroanatomical locations such as frontal, parietal, temporal,
occipital lobes, thalamus, lateral ventricles, hippocampus, midbrain, pons, medulla and
cerebellum (Supplementary Tables 1–3; Supplementary Fig. 1). For molecular studies
(RNA and DNA) 134 core punches were obtained using a biopsy punch and plunger
(2 mm, #33-31, Integra Miltex, York, PA). All histological sections were reviewed by
neuropathologists (C.-Y.H. and J.K.), according to the World Health Organization
(WHO) classiﬁcation of tumours. Demographical, clinical and histopathological
characteristics of all specimens are presented in Supplementary Table 1.
Immunohistochemistry. Immunohistochemistry was performed on 5 mm thick
formalin ﬁxed parafﬁn embedded (FFPE) slides. Brieﬂy, slides were de-parafﬁnized,
processed for epitope retrieval, DAB detected using reagents customized for the Leica
BOND-MAX automated stainer (Leica Biosystems, Buffalo Grove, IL). Processed
slides were probed by immunohistochemical assay for hematoxylin and eosin (H&E),
Ki67, H3-K27M and H3-K27me3 as previously described12 (Supplementary Fig. 2).
Antibodies. Rabbit monoclonal anti-Ki67 (Biocare Medical, Concord, CA) were
pre-diluted and ready to use. Rabbit polyclonal anti-H3K27M (#ABE419 Millipore,
Billerica, MA, 1:500), rabbit monoclonal anti-H3K27me3 (C36B11, #9733 Cell
Signaling, Beverly, MA 1:75) were diluted in Bond primary antibody diluent
(#AR9352 Leica Biosystems, Buffalo Grove, IL). Secondary detection was
conducted using the Bond polymer reﬁned detection kit (Leica Biosystems,
Buffalo Grove, IL). Slides were counterstained for hematoxylin nuclear stain.
RNA and DNA extractions. Frozen tissue samples were homogenized with Trizol,
and nucleic acids were phase separated using chloroform. Total RNA was extracted
according to the PicoPure RNA Isolation kit (Arctrus Bioscience Inc., Mountain
view, CA). Genomic DNA was extracted from frozen tissue using the Gentra
Puregene DNA extraction kit, or from FFPE tissue using the QiaAmp DNA mini
kit according to the manufacturer’s instructions (Qiagen, Valencia, CA). All DNA
quantiﬁcations were conducted using the Quant-iT Picogreen dsDNA assay kit
(Life Technologies, Carlsbad, CA).
Droplet digital PCR. Digital droplet PCR (ddPCR) assays were performed
according to standard methods. Brieﬂy, each 20 ml reaction contained 1  ddPCR
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Supermix for Probes (Bio-Rad), 900 nM gene speciﬁc HPLC-puriﬁed forward
and reverse primer, 250 nM gene-speciﬁc mutant or wild-type locked nucleic acid
(LNA) probe and 12.5–25.0 ng genomic DNA. Each reaction was mixed with 60 ml
Droplet Generation Oil (Bio-Rad), partitioned into B12,000–16,000 droplets in
QX100 Droplet Generator (Bio-Rad), transferred to a 96-well plate and sealed. The
primers and probes were designed by Integrated DNA Technologies as follows:
forward primer for H3F3A: 50 -GTACAAAGCAGACTGCCCGCAAAT-30 , reverse
primer; 50 -GTGGATACATACAAGAGAGACTTTGTCCC-30 . Forward primer for
HIST1H3B: 50 -ACAGACGTCTCTGCAGGCAAGC-30 , reverse primer 50 -GGCGG
TAACGGTGAGGCTTT-30 . H3F3A K27M wild-type probe (HEX) CA þ C þ T þ
C þ T þ T þ GC and mutant probe (FAM) CA þ CT þ C þ A þ T þ GCG.
HIST1H3B K27M wild-type probe (HEX) T þ CGC þ A þ A þ GAG þ CG and
mutant probe (FAM) TCGC þ A þ T þ G þ AGCG. The PCRs were performed in
a T100 Thermal Cycler (Bio-Rad) with the following cycling conditions: 1  (95 °C
for 10 min), 50  (95 °C for 30 s, 53 °C or 57 °C for 60 s, with 2 °C s  1 ramp rate
and 1  (98 °C for 10 min). Following end-point ampliﬁcation, the ﬂuorescence
intensity of individual droplets was measured with the QX100 Droplet Reader
(Bio-Rad) and data analysis was performed with QuantaSoft droplet reader
software (Bio-Rad). Positive and negative droplet populations were detected
either automatically or manually on two-dimensional graphs and target DNA
concentrations were calculated using the Poisson statistics28.The absolute
transcript levels were initially computed as copies per ml PCR for both mutant
and wild-type and then presented as per cent of total gene copy.
Whole-exome sequencing. Genomic DNA was extracted from multiple postmortem samples patient using the standard extraction methods as described by
Qiagen. Nextera Rapid Capture Exome kit was used to prepare the paired-end
libraries according to the manufacturer’s instructions using on average 36 ng of
total starting genomic DNA. Sequencing was performed on Illumina HiSeq 2000
using rapid-run mode with 100 bp paired-end reads. Next, adaptor sequences
were removed; reads were trimmed for quality using the FASTX-Toolkit (http://
hannonlab.cshl.edu/fastx_toolkit/). An in-house program was used to ensure the
presence of exclusively paired-reads to be used in further steps of the analysis.
We next aligned the reads using Burrows-Wheeler Aligner (BWA) 0.7.7 to hg19 as
reference genome. Indel realignment was performed using the Genome Analysis
Toolkit (GATK)29 (http://www.broadinstitute.org/gsa/wiki/). We next marked the
duplicate reads using Picard (http://picard.sourceforge.net/) and excluded them
from further analyses as previously described6. The coverage of consensus coding
sequence (CCDS) bases was assessed using GATK. The average coverage over
all the samples was 70  . The majority of samples had 490% of CCDS bases
covered by at least 10 reads and 483% of CCDS bases covered by at least
20 reads.
We called SNVs and short indels using SAMtools (http://samtools.sourceforge.
net/) mpileup with the extended base alignment quality adjustment (–E)30,31. Next
we ﬁltered them for quality so that at least 10% of reads supporting each variant
call. We used both ANNOVAR32 and in-house tools to annotate the variants and
to identify whether these variants affect protein-coding sequence and if they had
previously been observed in datasets including the 1,000 Genomes Project data set
(November 2011), the National Heart, Lung and Blood Institute (NHLBI) Grand
Opportunity (GO) exomes or in B3,000 exomes previously sequenced at our
center. Results of whole exome sequencing are summarized in Supplementary
Table 4 and presented for individual patients as follows: DIPG1 in Supplementary
Data 1; DIPG2 in Supplementary Data 2; DIPG3 in Supplementary Data 3;
DIPG4 in Supplementary Data 4; DIPG5 in Supplementary Data 5; DIPG6 in
Supplementary Data 6; DIPG7 in Supplementary Data 7; DIPG8 in Supplementary
Data 8; DIPG9 in Supplementary Data 9.
Exploratory targeted high-depth DNA sequencing of hotspot mutations.
Genomic DNA from DIPG samples were used for high-depth sequencing using
Illumina MiSeq platform. The MiSeq panel covers exons in 16 Histone H3 isoforms
(10 H3.1, 2 H3.2 and 3 H3.3 genes) and covering hotspot mutations such as IDH1
mutation (codon 132), IDH2 (codons 140 and 172), ACVR1 (exons 6–9) and BRAF
(exons 11 and 15) and PPM1D (exon 6). Genomic DNA samples were sequenced
using the MiSeq sequencing platform (Illumina) as previously described6 with an
average coverage of 420,000  of the analogous K27M base change across the
three histone variants.
To estimate allele frequency of mutations identiﬁed using whole exome
sequencing genomic DNA from the same samples was also used for high-depth
sequencing on the MiSeq platform with an average coverage of 44,000  . Reads
were mapped to the reference genome (human hg19) using the BWA genome
alignment30,31. Alignment ﬁles were fed to an in-house program to calculate
different variations’ allele frequencies at the desired positions.
RNA sequencing. We used Qiagen RNeasy Lipid Tissue Mini kit to extract RNA
from tumour DIPG3 (Pons 1 and Pons 2) according to manufacturer’s instructions.
Library was prepared using rRNA depletion methods according to instruction from
Epicentre (manufacturer) to achieve greater coverage of mRNA. Paired-end
sequencing was performed on the Illumina HiSeq 2000 platform.
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DNA methylation analysis. Methylation proﬁling data was analysed as previously
described6. The raw data were subject to quality control and preprocessing utilizing
the R package minﬁ, and normalized for technical variation between the Inﬁnium I
and II probes using the SWAN method. We removed probes on sex chromosomes
(chrX, Y), those containing SNPs (dbSNP: http://www.ncbi.nlm.nih.gov/SNP/) as
well as non-speciﬁc probes that bind to multiple genomic locations. Unsupervised
hierarchical clustering was performed using average linkage and Pearson rank
correlation distance on the top 5,000 most variable probes selected based on
standard deviation of beta values (b-values).
Copy number variation analysis. To study copy number variations in our
samples we developed an in-house program to calculate the deviation of B allele
frequency from 50% as well as normalized coverage from whole exome sequencing
data (adapted from methods used in FishingCNV33 and ExomeAI34). Different
CNV events (duplication, deletion and copy neutral LOH) were called based upon
the B allelic imbalance and the status of the normalized coverage as follow:
deviation from 50% B allele frequency and an increase in normalized coverage was
considered as ampliﬁcation, deviation from 50% B allele frequency and decrease in
normalized coverage as deletion and deviation from 50% B allele frequency and no
change in the normalized coverage was considered as potential copy neutral loss of
heterozygosity. We mainly assessed the CNV events at the chromosomal arm level.
The results of our CNV detection are presented in Supplementary Fig. 5 and
Supplementary Table 14.
OncoScan veriﬁcation of the CNV events. OncoScan FFPE Assay Kit, provided
by Affymetrix, is a platform based on Molecular Inversion Probe technology, used
to asses copy number and loss of heterozygosity using small amounts of DNA from
FFPE samples. We performed this assay on several samples in order to verify our
WES based CNV detection method. Genomic DNA was quantiﬁed using Picogreen
protocol (Quant-iT PicoGreen dsDNA Products, Invitrogen, P-7589) and read on
SpectraMAX GeminiXS Spectrophotometer. The OncoScan FFPE Assay Kit was
used according to the manufacturer’s instructions (Affymetrix). A GeneAmp PCR
system 9700 Thermal Cycler (Life Technologies) was used from the anneal stage
to the denaturation stage. QC gels of the PCR and HaeIII digest products were
performed on E-Gel 48.4% agarose gels using Mother E-Base device (Life
Technologies) and imaged with SYNGENE GeneGenius Bio Imaging System
(Syngene). The digest DNA target was hybridized on OncoScan array (Affymetrix)
and incubated at 49 °C in the Genechip Hybridization oven 640 (Affymetrix) for
17 h at 60 rpm. OncoScan arrays were then washed in a GeneChips Fluidics Station
450 (Affymetrix) using OncoScan stain and wash reagents according to the
manufacturer’s instructions (Affymetrix). The microarrays were ﬁnally scanned on
a GeneChip scanner 3,000 (Affymetrix). Data QC analysis was performed with the
OncoScan Consol 1.2.0.50 software (Affymetrix) using OncoScan Analysis Library
ﬁles r1.1. OncoScan positive and negative control supplied in the OncoScan
FFPE Assay Kit were used for internal controls to assess the performance of each
run. CNV events were called using the normalized data using Nexus Express
for OncoScan 3.1 (Affymetrix). The OncoScan plots are represented in
Supplementary Fig. 6.
Constructing evolutionary trees. We used PhyloWGS35 to reconstruct the
tumour phylogeny, which uses a Bayesian approach to infer cellular frequencies
from mutation allele frequencies. It applies Dirichlet process to cluster mutations
with similar cellular frequencies and the tree-structured stick-breaking process to
model the clonal evolutionary tree. For multi-region samples from the same
patient, we normalized the read counts used for phylogenetic tree construction by
copy number counts from CNV analysis. Read counts were corrected for the CNV
events (Supplementary Fig. 5; Supplementary Table 3) for each sample as follow: in
case of duplication Ref 0 ¼ Ref, Alt0 ¼ Alt/2; in case of deletion Ref 0 ¼ Ref þ Alt,
Alt0 ¼ Alt; in case of a gene on chromosome X Ref 0 ¼ Ref  2 þ Alt, Alt0 ¼ Alt; in
case of Copy Neutral LOH Ref 0 ¼ Ref þ Alt/2 and Alt0 ¼ Alt/2. The reconstructed
trees were redrawn in Graphviz by using in-house scripts adapted from
AncesTree36 to show the trajectories of mutations with contribution Z0.05.
Differential expression and gene set enrichment analysis. We aligned RNASeq
data from DIPG3-Pons 1 and DIPG3-Pons 2 (RNA extraction and sequencing
protocol described before) using STAR 2.3.0 (ref. 37), and analysed differentially
expressed genes using DeSEQ2 (ref. 36). The top 200 over expressed and top
200 under expressed genes in DIPG3-Pons 2 (the sub-clone with PIK3CA
activating mutation) were analysed for geneset enrichment using both AmiGo
2 tool38 (http://amigo.geneontology.org/amigo) provided by Gene Ontology and
DAVID39 (https://david.ncifcrf.gov/). We used PANTHER Overrepresentation
Test (release 20,150,430) for analysis type by Amigo 2 (annotation version and
release date: GO Ontology database released 2015-08-06). The top pathways
found by AmiGo 2 to be enriched with enrichment folds higher than 5 and
(Bonferronio0.05) were retained. We used functional annotation clustering and
set the stringency to the highest in DAVID and ﬁltered the results for enrichment
folds higher than 5 (Bonferroni corrected P valueo0.05). We used the set of genes
with at least 50 RNASeq reads in both DIPG3 Pons1

and 2 combined as background gene set in this analysis (Supplementary
Data 10).
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